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their index cath (MI Group) or as being event-free at three
months (No MI Group). Outcomes through four years were
assessed in landmark analyses using Cox proportional hazards
techniques. RESULTS: Patients in the MI vs. No MI Groups had
a median of 4.2 years follow-up and were similar in age (62 vs.
63 years, p = .44), female sex (35% vs. 33%, p = .35), history of
hypertension (69% vs. 68%, p = .77), history of diabetes (35%
vs. 30%, p = .08), and in multi-vessel CAD (61% vs. 58%,
p = .17). At four years follow-up, patients in the MI vs. No MI
Groups had higher unadjusted rates of death (25% vs. 17%,
p < .001) and death or MI (34% vs. 21%, p < .001). After
adjustment, the hazards of death for patients in the MI vs.
No-MI Groups (HR 1.62; 95% CI 1.30, 2.02; p < .001) and
death or MI (HR 1.84; 95% CI 1.51, 2.24, p < .001) remained
signiﬁcant. When we extended the landmark period from three to
six months after the index cath, the adjusted hazards of death
(HR 1.61; 95% CI 1.34, 1.93; p < .001) and death or MI (HR
1.86; 95% CI 1.58, 2.19; p < .001) were still signiﬁcant. CON-
CLUSIONS: Non-fatal myocardial infarctions signiﬁcantly
increase subsequent rates of death and death or MI in CAD
patients. These ﬁndings suggest a long-term clinical beneﬁt for
therapies that avert non-fatal MIs.
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OBJECTIVES: To assess AF-QoL questionnaire performance in
patients with Atrial Fibrillation (AF) in a usual clinical practice
setting. METHODS: Observational, prospective, multicenter
studywas carried out in 29 Spanish centres. AF diagnosed patients
aged 18 who have changed a clinical and/or therapeutic inter-
vention or were stable according to clinical criteria, and patients
with post heart attack cardiopathy (control group) were enrolled.
All patients went through a baseline visit; only AF patients
underwent a follow up visit (at 3  1 months and 1 month for
unstable and stable patients respectively). At each visit, socio-
demographical and clinical information was gathered; AF-QoL,
SF-36 questionnaires and perception of general health status were
administered. AF-QoL is an 18-item questionnaire with 3
domains: psychological, physical and sexual. Questions refer to
previous month. Answers are 5 levels Likert-like. AF-QoL scores
range between 0–100,where 0 is poorHRQoL.RESULTS:A total
of 417 patients were included: 341 AF patients and 76 control
patients. Mean (SD) age was 61.2(12.4) and 31.4% were women.
AF type distribution was: 37.5% paroxysmal, 42.9% persistent
and 19.6% permanent. AF-QoL was completed by 88.5% of
patients. AF-QoL mean overall global score in AF patients was
43.6 and 51.7 in control group (p < 0.05). AF-QoL showed good
internal consistency (0.92) and good test-retest reliability (0.86) in
stable AF patients. Patients with more symptoms and worse
NYHA functional class at baseline and at the end of follow-up
visit showed lower scores in AF-QoL. AF-QoL correlations with
SF-36 and overall perception of general health status question
were moderate-high (0.32–0.69) and moderate (0.49) (p < 0.01)
repectively. AF-QoL effect size scores in patients declaring health
status positive changes was 1.06, 0.2 for those with no changes
and 0.1 for patients with negative changes. CONCLUSIONS:
AF-Qol has shown to be feasible, valid, reliable and responsive to
clinical changes in the context of clinical practice.
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OBJECTIVES: To predict the percentage of patients achieving
multiple optimal lipid values (OLV) after one year of combina-
tion fenoﬁbric acid (FA) + statin therapy or statin monotherapy.
METHODS: A dyslipidemia outcomes model was used to predict
multiple OLV attainment (any 3 of 4 targets: total-C, LDL-C,
HDL-C, or TG) among a cohort of 1000 patients with multiple
lipid abnormalities (MLA). Optimal lipid levels for HDL-C
(value >40 mg/dL for men, >50 mg/dL for women), LDL-C
(value <130 mg/dL), TG (value <150 mg/dL), and total-C (value
<210 mg/dL) were based on U.S. clinical practice guidelines.
Baseline lipid values were simulated with National Health and
Nutrition Examination Survey data, used to determine the shape
of lipid distributions (gamma for TG and log normal for the
others) and the correlation between these parameters. Mean
initial and on-treatment lipid values were obtained from three
12-week FA/statin studies, where FA 135 mg co-administered
with atorvastatin, rosuvastatin, and simvastatin at low (20 mg,
10 mg, 20 mg, respectively) and moderate doses (40 mg, 20 mg,
40 mg, respectively) was compared to FA and corresponding
statin monotherapy doses. RESULTS: Compared to equivalent
statin monotherapy, the addition of FA 135 mg to low-dose
simvastatin, rosuvastatin, and atorvastatin was predicted to
result in 43% (678 vs. 473 per 1000), 31% (814 vs. 621 per
1000), and 43% (723 vs. 506 per 1\000) more patients simulta-
neously achieving multiple OLV. The number of patients pre-
dicted to achieve multiple OLV increased by 16%, 18% and 25%
with FA + moderate-dose simvastatin, rosuvastatin, and atorvas-
tatin over equivalent dose statin monotherapy, respectively.
CONCLUSIONS: Patients with MLA receiving statin mono-
therapy may require add-on treatment to achieve multiple lipid
targets. This analysis suggests that treatment with FA in combi-
nation with low- and moderate-dose statin therapy may enable
more patients to simultaneously achieve OLV compared to statin
monotherapy.
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OBJECTIVES: To assess the cost-effectiveness of ivabradine in
stable angina patients in the Dutch health care setting in 2007.
METHODS: A Markov model was developed to estimate the
cost-effectiveness of ivabradine. The analysis was performed for
stable angina patients, who currently are candidate for revascu-
larisation. Data sources used included 1) Ivabradine clinical trial
data, 2) Data of the Dutch Heart Foundation, and 3) Data of the
Euro Heart Survey (European Cardiology database). Further-
more, published literature, ofﬁcial Dutch price/tariff lists and
national population statistics are used. The time horizon of the
model was 5 years in order to capture the long-term economic
impact of ivabradine. RESULTS: The results show that the use of
ivabradine leads to additional drug costs of €3873 over a period
of 5 years, which are offset by a cost saving of €8699 due to fewer
revascularisations (€1210 in the ivabradine arm versus €9909 in
the revascularisation arm) over a period of 5 years. As a result the
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